Effect of mirtazapine treatment on body composition and metabolism

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 421-424

  Laimer, Markus ^a   Kramer Reinstadler, Karin ^b   Rauchenzauner, Markus ^a   Lechner Schoner, Theresia ^b   Strauss, Robert ^b   Engl, Julia ^a   Deisenhammer, Eberhard A ^b   Hinterhuber, Hartmann ^b   Patsch, Josef R ^a   Ebenbichler, Christoph F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; GLUCOSE; INSULIN; LEPTIN; LEPTIN RECEPTOR; LIPOPROTEIN; MIRTAZAPINE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

EID: 33645790328     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0313     Document Type: Article

References (24)

1. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(suppl 11):37-41
2. Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220-225
3. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607-631
4. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21
5. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000;23:13-19
6. Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984;7:133-138
7. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73
8. Puzantian T. Mirtazapine: an antidepressant. Am J Health Syst Pharm 1998;55:44-49
9. Fernstrom MH. Drugs that cause weight gain. Obes Res 1995;3(suppl 4):435S-439S
10. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001;158:1719-1722
11. Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998;3:76-80
12. Melkersson KI, Hulling AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-791
13. Laimer M, Ebenbichler CF, Kranebitter M, et al. Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors [letter]. J Clin Psychopharmacol 2005;25:183-185
14. Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003;64: 1436-1439
15. Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005;10:1089-1096
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
17. Laimer M, Ebenbichler CF, Kaser S, et al. Weight loss increases soluble leptin receptor levels and the soluble receptor bound fraction of leptin. Obes Res 2002;10:597-601
18. Sandhofer A, Laimer M, Ebenbichler CF, et al. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res 2003;11:760-768
19. Eder-Ischia U, Ebenbichler C, Fleischhacker WW. Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essent Psychopharmacol 2005;6:112-117
20. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
21. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65 (suppl 7):4-18; quiz 19-20
22. Grohmann R, Engel RR, Geissler KH, et al. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004;37(suppl 1):S27-S38
23. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003;64:883-889
24. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-1161